BACKGROUND/ OBJECTIVE: The risk of recurrent tuberculosis may increase in HIV-infected patients due to exogenous reinfection. We measured the frequency of and determined risk factors for recurrent tuberculosis in a cohort of HIV-infected patients in Rio de Janeiro, Brazil. METHODS: Data were abstracted from medical records of HIV-infected patients attending 29 HIV clinics between 1998 and 2007. Patients analyzed were those who had no tuberculosis history prior to their first HIV clinic visit and who had at least one episode of tuberculosis after entry. Incidence rate ratios compared incidence rates between risk groups and Cox proportional hazards regression models evaluated unadjusted and adjusted associations. RESULTS: Among 1080 HIV-infected patients with tuberculosis, 96 (8.9%) developed a recurrent diagnosis. The median time between diagnoses was 2.4 years. Fewer patients with recurrent tuberculosis had completed their initial 6-month course of tuberculosis treatment compared with patients without recurrence (78 versus 86%; P = 0.02). For patients who completed therapy, the incidence rate of recurrence was 2.5/100 versus 9.0/100 person-years for noncompleters (incidence rate ratio, 3.60; 95% confidence interval, 1.92-6.32). In multivariate modeling, initial tuberculosis treatment completion, receipt of antiretroviral therapy, and CD4 cell count more than 200 mm any time after the initial diagnosis were associated with a significantly decreased hazard of recurrence. CONCLUSION: Tuberculosis recurrence rates were high in this HIV-infected population. Completion of initial tuberculosis therapy, use of antiretroviral therapy, and increases in CD4 cell counts were associated with lower recurrence rates. Use of secondary preventive therapy might be warranted to reduce the burden of tuberculosis in patients with HIV infection.
BACKGROUND/ OBJECTIVE: The risk of recurrent tuberculosis may increase in HIV-infectedpatients due to exogenous reinfection. We measured the frequency of and determined risk factors for recurrent tuberculosis in a cohort of HIV-infectedpatients in Rio de Janeiro, Brazil. METHODS: Data were abstracted from medical records of HIV-infectedpatients attending 29 HIV clinics between 1998 and 2007. Patients analyzed were those who had no tuberculosis history prior to their first HIV clinic visit and who had at least one episode of tuberculosis after entry. Incidence rate ratios compared incidence rates between risk groups and Cox proportional hazards regression models evaluated unadjusted and adjusted associations. RESULTS: Among 1080 HIV-infectedpatients with tuberculosis, 96 (8.9%) developed a recurrent diagnosis. The median time between diagnoses was 2.4 years. Fewer patients with recurrent tuberculosis had completed their initial 6-month course of tuberculosis treatment compared with patients without recurrence (78 versus 86%; P = 0.02). For patients who completed therapy, the incidence rate of recurrence was 2.5/100 versus 9.0/100 person-years for noncompleters (incidence rate ratio, 3.60; 95% confidence interval, 1.92-6.32). In multivariate modeling, initial tuberculosis treatment completion, receipt of antiretroviral therapy, and CD4 cell count more than 200 mm any time after the initial diagnosis were associated with a significantly decreased hazard of recurrence. CONCLUSION:Tuberculosis recurrence rates were high in this HIV-infected population. Completion of initial tuberculosis therapy, use of antiretroviral therapy, and increases in CD4 cell counts were associated with lower recurrence rates. Use of secondary preventive therapy might be warranted to reduce the burden of tuberculosis in patients with HIV infection.
Authors: F Gordin; R E Chaisson; J P Matts; C Miller; M de Lourdes Garcia; R Hafner; J L Valdespino; J Coberly; M Schechter; A J Klukowicz; M A Barry; R J O'Brien Journal: JAMA Date: 2000-03-15 Impact factor: 56.272
Authors: L Haller; R Sossouhounto; I M Coulibaly; M Dosso; M Kone; H Adom; U A Meyer; B Betschart; M Wenk; W E Haefeli; L R Lobognon; M Porquet; G Kaboré; F Sorenson; R Reber-Liske; D Stürchler Journal: Chemotherapy Date: 1999 Nov-Dec Impact factor: 2.544
Authors: Lawrence H Moulton; Jonathan E Golub; Betina Durovni; Solange C Cavalcante; Antonio G Pacheco; Valeria Saraceni; Bonnie King; Richard E Chaisson Journal: Clin Trials Date: 2007 Impact factor: 2.486
Authors: Beatriz Grinsztejn; Valdilea G Veloso; José Henrique Pilotto; Dayse Pereira Campos; Jeanne C Keruly; Richard D Moore Journal: J Acquir Immune Defic Syndr Date: 2007-08-15 Impact factor: 3.731
Authors: Jonathan E Golub; Valeria Saraceni; Solange C Cavalcante; Antonio G Pacheco; Lawrence H Moulton; Bonnie S King; Anne Efron; Richard D Moore; Richard E Chaisson; Betina Durovni Journal: AIDS Date: 2007-07-11 Impact factor: 4.177
Authors: S D Lawn; A D Harries; B G Williams; R E Chaisson; E Losina; K M De Cock; R Wood Journal: Int J Tuberc Lung Dis Date: 2011-05 Impact factor: 2.373
Authors: Timothy Lahey; Todd Mackenzie; Robert D Arbeit; Muhammad Bakari; Lillian Mtei; Mecky Matee; Isaac Maro; C Robert Horsburgh; Kisali Pallangyo; C Fordham von Reyn Journal: Clin Infect Dis Date: 2012-09-12 Impact factor: 9.079
Authors: Jason R Andrews; Stephen D Lawn; Corina Rusu; Robin Wood; Farzad Noubary; Melissa A Bender; C Robert Horsburgh; Elena Losina; Kenneth A Freedberg; Rochelle P Walensky Journal: AIDS Date: 2012-05-15 Impact factor: 4.177